Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children

Ting Rong Hsu, Tai-Tong Wong, Feng Chi Chang, Donald M. Ho, Ren Bin Tang, Peck Foong Thien, Kai Ping Chang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Though the pathology of optic pathway tumor is mostly pilocytic astrocytoma, the benign tumor behaves like malignant tumor because total resection is not feasible. Adjuvant chemotherapy might be a reasonable strategy for management of these low grade tumors which keep growing. We evaluate the responsiveness of optic pathway tumor to cisplatin-based chemotherapy. Methods: Patients with unresectable and progressive optic pathway tumors received conventional chemotherapy including cisplatin, etoposide, and vinblastine were enrolled in this study from 1992 to 2007. Patients treated with radiotherapy previously were excluded. Brain MRI was performed every 3 months to evaluate the objective response to chemotherapy. Results: There are seven girls and nine boys enrolled in this study. The median age at diagnosis was 30 months old (range from 3 months to 11 years old). The median follow-up duration was 81.5 months (range from 24 months to 14.5 years). The pathology showed pilocytic astrocytomas in 11 patients, astrocytoma in one patient, and anaplastic astrocytomas in two patients. The 6-month progression-free survival (PFS) is 100%, 12-month PFS is 81.3%, 3-year PFS is 71.4% and 5-year PFS is 55.5% respectively. The toxicity of the cisplatin-based chemotherapy showed mild bone marrow suppression in 13 patients (81.3%), infection in nine patients (56.3%), gastrointestinal discomfort in seven patients (43.8%), renal insufficiency in two patient (12.5%), cerebral salt wasting syndrome with hyponatremia in one patient (6.25%) and high pitch hearing loss in two patients (12.5%). Conclusion: Cisplatin-based chemotherapy is an effective regimen for control of progressive optic pathway tumors.

Original languageEnglish
Pages (from-to)1457-1461
Number of pages5
JournalChild's Nervous System
Volume24
Issue number12
DOIs
Publication statusPublished - Sep 5 2008
Externally publishedYes

Fingerprint

Cisplatin
Drug Therapy
Neoplasms
Astrocytoma
Disease-Free Survival
Pathology
Wasting Syndrome
Vinblastine
Hyponatremia
Etoposide
Adjuvant Chemotherapy
Hearing Loss
Renal Insufficiency
Radiotherapy
Salts
Bone Marrow
Brain
Infection

Keywords

  • Brain tumor
  • Chemotherapy
  • Cisplatin
  • Optic pathway tumor
  • Pediatric

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. / Hsu, Ting Rong; Wong, Tai-Tong; Chang, Feng Chi; Ho, Donald M.; Tang, Ren Bin; Thien, Peck Foong; Chang, Kai Ping.

In: Child's Nervous System, Vol. 24, No. 12, 05.09.2008, p. 1457-1461.

Research output: Contribution to journalArticle

Hsu, Ting Rong ; Wong, Tai-Tong ; Chang, Feng Chi ; Ho, Donald M. ; Tang, Ren Bin ; Thien, Peck Foong ; Chang, Kai Ping. / Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. In: Child's Nervous System. 2008 ; Vol. 24, No. 12. pp. 1457-1461.
@article{550cc5c3be6a4275aae40c12a70ff7b5,
title = "Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children",
abstract = "Background: Though the pathology of optic pathway tumor is mostly pilocytic astrocytoma, the benign tumor behaves like malignant tumor because total resection is not feasible. Adjuvant chemotherapy might be a reasonable strategy for management of these low grade tumors which keep growing. We evaluate the responsiveness of optic pathway tumor to cisplatin-based chemotherapy. Methods: Patients with unresectable and progressive optic pathway tumors received conventional chemotherapy including cisplatin, etoposide, and vinblastine were enrolled in this study from 1992 to 2007. Patients treated with radiotherapy previously were excluded. Brain MRI was performed every 3 months to evaluate the objective response to chemotherapy. Results: There are seven girls and nine boys enrolled in this study. The median age at diagnosis was 30 months old (range from 3 months to 11 years old). The median follow-up duration was 81.5 months (range from 24 months to 14.5 years). The pathology showed pilocytic astrocytomas in 11 patients, astrocytoma in one patient, and anaplastic astrocytomas in two patients. The 6-month progression-free survival (PFS) is 100{\%}, 12-month PFS is 81.3{\%}, 3-year PFS is 71.4{\%} and 5-year PFS is 55.5{\%} respectively. The toxicity of the cisplatin-based chemotherapy showed mild bone marrow suppression in 13 patients (81.3{\%}), infection in nine patients (56.3{\%}), gastrointestinal discomfort in seven patients (43.8{\%}), renal insufficiency in two patient (12.5{\%}), cerebral salt wasting syndrome with hyponatremia in one patient (6.25{\%}) and high pitch hearing loss in two patients (12.5{\%}). Conclusion: Cisplatin-based chemotherapy is an effective regimen for control of progressive optic pathway tumors.",
keywords = "Brain tumor, Chemotherapy, Cisplatin, Optic pathway tumor, Pediatric",
author = "Hsu, {Ting Rong} and Tai-Tong Wong and Chang, {Feng Chi} and Ho, {Donald M.} and Tang, {Ren Bin} and Thien, {Peck Foong} and Chang, {Kai Ping}",
year = "2008",
month = "9",
day = "5",
doi = "10.1007/s00381-008-0707-4",
language = "English",
volume = "24",
pages = "1457--1461",
journal = "Child's Nervous System",
issn = "0256-7040",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children

AU - Hsu, Ting Rong

AU - Wong, Tai-Tong

AU - Chang, Feng Chi

AU - Ho, Donald M.

AU - Tang, Ren Bin

AU - Thien, Peck Foong

AU - Chang, Kai Ping

PY - 2008/9/5

Y1 - 2008/9/5

N2 - Background: Though the pathology of optic pathway tumor is mostly pilocytic astrocytoma, the benign tumor behaves like malignant tumor because total resection is not feasible. Adjuvant chemotherapy might be a reasonable strategy for management of these low grade tumors which keep growing. We evaluate the responsiveness of optic pathway tumor to cisplatin-based chemotherapy. Methods: Patients with unresectable and progressive optic pathway tumors received conventional chemotherapy including cisplatin, etoposide, and vinblastine were enrolled in this study from 1992 to 2007. Patients treated with radiotherapy previously were excluded. Brain MRI was performed every 3 months to evaluate the objective response to chemotherapy. Results: There are seven girls and nine boys enrolled in this study. The median age at diagnosis was 30 months old (range from 3 months to 11 years old). The median follow-up duration was 81.5 months (range from 24 months to 14.5 years). The pathology showed pilocytic astrocytomas in 11 patients, astrocytoma in one patient, and anaplastic astrocytomas in two patients. The 6-month progression-free survival (PFS) is 100%, 12-month PFS is 81.3%, 3-year PFS is 71.4% and 5-year PFS is 55.5% respectively. The toxicity of the cisplatin-based chemotherapy showed mild bone marrow suppression in 13 patients (81.3%), infection in nine patients (56.3%), gastrointestinal discomfort in seven patients (43.8%), renal insufficiency in two patient (12.5%), cerebral salt wasting syndrome with hyponatremia in one patient (6.25%) and high pitch hearing loss in two patients (12.5%). Conclusion: Cisplatin-based chemotherapy is an effective regimen for control of progressive optic pathway tumors.

AB - Background: Though the pathology of optic pathway tumor is mostly pilocytic astrocytoma, the benign tumor behaves like malignant tumor because total resection is not feasible. Adjuvant chemotherapy might be a reasonable strategy for management of these low grade tumors which keep growing. We evaluate the responsiveness of optic pathway tumor to cisplatin-based chemotherapy. Methods: Patients with unresectable and progressive optic pathway tumors received conventional chemotherapy including cisplatin, etoposide, and vinblastine were enrolled in this study from 1992 to 2007. Patients treated with radiotherapy previously were excluded. Brain MRI was performed every 3 months to evaluate the objective response to chemotherapy. Results: There are seven girls and nine boys enrolled in this study. The median age at diagnosis was 30 months old (range from 3 months to 11 years old). The median follow-up duration was 81.5 months (range from 24 months to 14.5 years). The pathology showed pilocytic astrocytomas in 11 patients, astrocytoma in one patient, and anaplastic astrocytomas in two patients. The 6-month progression-free survival (PFS) is 100%, 12-month PFS is 81.3%, 3-year PFS is 71.4% and 5-year PFS is 55.5% respectively. The toxicity of the cisplatin-based chemotherapy showed mild bone marrow suppression in 13 patients (81.3%), infection in nine patients (56.3%), gastrointestinal discomfort in seven patients (43.8%), renal insufficiency in two patient (12.5%), cerebral salt wasting syndrome with hyponatremia in one patient (6.25%) and high pitch hearing loss in two patients (12.5%). Conclusion: Cisplatin-based chemotherapy is an effective regimen for control of progressive optic pathway tumors.

KW - Brain tumor

KW - Chemotherapy

KW - Cisplatin

KW - Optic pathway tumor

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=56349128627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349128627&partnerID=8YFLogxK

U2 - 10.1007/s00381-008-0707-4

DO - 10.1007/s00381-008-0707-4

M3 - Article

VL - 24

SP - 1457

EP - 1461

JO - Child's Nervous System

JF - Child's Nervous System

SN - 0256-7040

IS - 12

ER -